GSK (GSK) Stock Overview

Engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. More details

GSK fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	2/6
Past Performance	4/6
Financial Health	3/6
Dividends	3/6

Rewards

Trading at 64.7% below our estimate of its fair value

Earnings are forecast to grow 9.9% per year

Earnings grew by 40.8% over the past year

Trading at good value compared to peers and industry

Risk Analysis

Large one-off items impacting financial results

Has a high level of debt

Unstable dividend track record

GSK Community Fair Values

Create Narrative

See what 69 others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW440,641 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

440,641 investors already sharing narratives

View all narratives

GSK plc Competitors

Price History & Performance

Summary of share price highs, lows and changes for GSK
Historical stock prices
Current Share Price	UK£48.13
52 Week High	UK£61.70
52 Week Low	UK£39.29
Beta	0.29
1 Month Change	-2.81%
3 Month Change	-7.85%
1 Year Change	17.88%
3 Year Change	28.59%
5 Year Change	-1.09%
Change since IPO	-30.47%

Recent News & Updates

Seeking Alpha • Aug 27

GSK: Still One Of My Top Healthcare Picks

Summary H2 2026/Q1 2027 will be rich in catalysts. From the potential FDA approval of bepirovirsen, with a target action date of October 26, for the treatment of chronic hepatitis B, to the Phase 3 OCEAN study results. By the way, Hibsago [bepirovirsen] was approved by Japan’s Ministry of Health, Labour, and Welfare on August 24. Meanwhile, GSK reaffirmed its 2026 guidance, expecting 3%-5% turnover growth and 7%-9% Core EPS growth. In this article, I explain why GSK, one of my top picks in HIV and vaccines, still offers an appealing risk/reward profile. Read the full article on Seeking Alpha

Recent updates

Seeking Alpha • Aug 27

GSK: Still One Of My Top Healthcare Picks

Shareholder Returns

	GSK	US Pharmaceuticals	US Market
7D	-3.5%	-3.4%	-0.9%
1Y	17.9%	44.7%	14.2%

Return vs Industry: GSK underperformed the US Pharmaceuticals industry which returned 44.7% over the past year.

Return vs Market: GSK exceeded the US Market which returned 14.1% over the past year.

Price Volatility

Is GSK's price volatile compared to industry and market?
GSK volatility
GSK Average Weekly Movement	3.7%
Pharmaceuticals Industry Average Movement	8.6%
Market Average Movement	6.9%
10% most volatile stocks in US Market	15.3%
10% least volatile stocks in US Market	2.9%

Stable Share Price: GSK has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: GSK's weekly volatility (4%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1715	66,841	Luke Miels	www.gsk.com

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer.

GSK plc Fundamentals Summary

How do GSK's earnings and revenue compare to its market cap?
GSK fundamental statistics
Market cap	US$95.96b
Earnings (TTM)	US$6.52b
Revenue (TTM)	US$44.91b

14.7x

P/E Ratio

2.1x

P/S Ratio

Is GSK overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GSK income statement (TTM)
Revenue	UK£33.20b
Cost of Revenue	UK£8.80b
Gross Profit	UK£24.40b
Other Expenses	UK£19.58b
Earnings	UK£4.82b

Last Reported Earnings

Jun 30, 2026

Next Earnings Date

Oct 28, 2026

Earnings per share (EPS)	1.20
Gross Margin	73.49%
Net Profit Margin	14.52%
Debt/Equity Ratio	106.5%

How did GSK perform over the long term?

See historical performance and comparison

Dividends

4.1%

Current Dividend Yield

57%

Payout Ratio

Does GSK pay a reliable dividends?

See GSK dividend history and benchmarks

When do you need to buy GSK by to receive an upcoming dividend?
GSK dividend dates
Ex Dividend Date	Aug 14 2026
Dividend Pay Date	Oct 08 2026
Days until Ex dividend	30 days
Days until Dividend pay date	25 days

Does GSK pay a reliable dividends?

See GSK dividend history and benchmarks

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/09/13 05:06
End of Day Share Price	2026/09/11 00:00
Earnings	2026/06/30
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

GSK plc is covered by 48 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
John Eade	Argus Research Company
Odile Rundquist	Baader Helvea Equity Research
Xue Chen	Barclays

GSK (GSK) Stock Overview

Rewards

Risk Analysis

Join community and earn perks

GSK plc Competitors

Bristol-Myers Squibb

Pfizer

Teva Pharmaceutical Industries

Royalty Pharma

Price History & Performance

Recent News & Updates

GSK PLC Receives Approval For Shingrix Prefilled Syringe Presentation In Japan

Gsk Advances Mrna Flu Vaccine Candidate to Phase Iii Following Positive Phase Ii Data

GSK: Still One Of My Top Healthcare Picks

GSK plc Announces Jemperli Accepts for Priority Review by US FDA for dMMR/MSI-H Locally Advanced Rectal Cancer

Gsk plc Declares Second Interim Dividend for the Second Quarter of 2026, Payable on 8 October 2026

Gsk plc Licensor Hansoh Pharmaceutical Group Announces Positive Results from Second Phase Iii Trial for Ris-Rez in China

Recent updates

GSK PLC Receives Approval For Shingrix Prefilled Syringe Presentation In Japan

Gsk Advances Mrna Flu Vaccine Candidate to Phase Iii Following Positive Phase Ii Data

GSK: Still One Of My Top Healthcare Picks

GSK plc Announces Jemperli Accepts for Priority Review by US FDA for dMMR/MSI-H Locally Advanced Rectal Cancer

Gsk plc Declares Second Interim Dividend for the Second Quarter of 2026, Payable on 8 October 2026

Gsk plc Licensor Hansoh Pharmaceutical Group Announces Positive Results from Second Phase Iii Trial for Ris-Rez in China

GSK Plc Receives FDA Approval For Jideytro In US For ROS1-Positive Non-Small Cell Lung Cancer

Gsk plc Receives European Medicines Agency Acceptance for Submission to Update Bexsero Label for 1-Dose Meningitis B Booster in Individuals Aged 10 Years and Older

Gsk plc Provides Update on Calm-1 and Calm-2 Phase III Trials for Camlipixant in Refractory Chronic Cough

GSK Plc Announces Positive Interim Results From AZUR-1 Phase II Trial Of Jemperli In dMMR/MSI-H Locally Advanced Rectal Cancer

Gsk plc Announces Appointment of Roy Jakobs to Non-Executive Director, Effective July 13, 2026

GSK plc Receives US FDA Approval for Oral Antibiotic Tebipenem for Complicated Urinary Tract Infections

GlaxoSmithKline LLC entered into an Agreement and Plan of Merger to acquire Nuvalent, Inc. (NasdaqGS:NUVL) for $10 billion.

Sino Biopharmaceutical Limited Presents Data From Two Phase III Clinical Trials Of Bepirovirsen At EASL 2026

GSK PLC Reports Positive Phase 3 Data For Bepirovirsen In Chronic Hepatitis B

GSK plc to Report Q3, 2026 Results on Oct 28, 2026

Gsk plc Receives Expanded Approval in Japan for Adults Aged 18-59 At Increased Risk

GSK plc Announces Bepirovirsen Accepted for Priority Review and Granted Breakthrough Therapy Designation by the US FDA

Gsk plc Receives US FDA Breakthrough Therapy and Ema Priority Medicines (Prime) Designations for Mash

GSK plc to Report Q1, 2026 Results on Apr 29, 2026

GSK plc Announces the National Medical Products Administration of China Has Approved Blenrep (Belantamab Mafodotin) in Combination with Bortezomib and Dexamethasone (BVd) for the Treatment of Adults with Relapsed or Refractory Multiple Myeloma

GSK plc Receives Additional Marketing Approval for Depemokimab

GSK plc (LSE:GSK) completed the acquisition of 35Pharma Inc.

Bioversys Ag Publishes Pre-Clinical Data of Alpe Drug Combination in Nature Communications

GSK plc Announces Exdensur Approval for CRSwNP in China

Samsung Biologics America, Inc completed the acquisition of Human Genome Sciences Inc. from GSK plc (LSE:GSK).

Bepirovirsen Accepted for Regulatory Review in China as A Potential First-In-Class Functional Cure for Chronic Hepatitis B

GSK PLC Bepirovirsen Accepted For Review By The European Medicines Agency As A Potential First-In-Class Treatment For Chronic Hepatitis B

GSK plc, Annual General Meeting, May 06, 2026

US Food and Drug Administration Approves GSK plc's Lynavoy(linerixibat)

GSK plc Announces Expansion of AREXVY Approval to Adults Aged 18 to 49 Years for RSV Prevention

Angeion Group Announces Proposed Settlement in DeCostanzo v. GlaxoSmithKline

GSK plc Appoints Elizabeth McKee Anderson as Member of the Corporate Responsibility Committee, Effective March 9, 2026

GSK plc (LSE:GSK) completed the acquisition of 93.4% stake in RAPT Therapeutics, Inc. (NasdaqGM:RAPT) for $1.7 billion.

GSK plc Announces That Japan's Ministry of Health, Labour and Welfare Accepts for Review A New Drug Application for Bepirovirsen

GSK plc (LSE:GSK) entered an agreement to acquire 35Pharma Inc for CAD 950 million.

GSK plc Announces New Effectiveness Data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) At RSVVW'26

GSK plc's RSV Vaccine Accepts for Review by China's Center for Drug Evaluation for the Prevention of Lower Respiratory Syncytial Virus Disease

GSK plc Announces Nucala (Mepolizumab) Approval by European Commission for Treatment of Chronic Obstructive Pulmonary Disease (COPD)

Gsk Plc's Rsv Vaccine Receives European Approval for Expanded Use in All Adults 18 Years and Older

GSK plc (LSE:GSK) entered a definitive agreement to acquire RAPT Therapeutics, Inc. (NasdaqGM:RAPT) for $1.7 billion.

GSK plc to Report Q4, 2025 Results on Feb 04, 2026

GSK plc Appoints Luke Victor Miels as Director, Effective January 1, 2026

GSK plc Announces Positive Topline Results from B-Well 1 and B-Well 2 Phase 3 Studies for Bepirovirsen

GSK plc Announces the Approval of Exdensur ( Depemokimab) by Japan's Ministry of Health, Labour and Welfare

GSK plc Announces China's National Medical Products Administration Approval of Nucala (Mepolizumab) as Add-On Maintenance Treatment of Adult Patients with Inadequately Controlled COPD

Samsung Biologics America, Inc. entered into a definitive agreement to acquire Human Genome Sciences Inc. from GSK plc (LSE:GSK) for $280 million.

Spero Therapeutics, Inc. Announces Nda Resubmission of Tebipenem Hbr by Gsk to the Fda for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis

GSK plc Announces Exdensur (depemokimab) Approved by US FDA for the Treatment of Severe Asthma

GSK plc Announces the Marketing Authorisation of Exdensur ( Depemokimab) by the UK's Medicines and Healthcare Products Regulatory Agency

GSK plc Announces US FDA Approval Of Blujepa For Gonorrhoea Indication

GSK plc Receives Orphan Drug Designation from US Food and Drug Administration for the Treatment of Small-Cell Lung Cancer

GSK plc Upgrades Earnings Guidance for the Year Ending December 31, 2025

GSK plc Announces US FDA Approves Blenrep (Belantamab Mafodotin-Blmf) in Combination with Bortezomib and Dexamethasone (BVd) for Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma

GSK plc Announces Positive Phase III Data for Next-Generation Low Carbon Version of Ventolin Metered Dose Inhaler

GSK's Shingrix New Prefilled Syringe Presentation Receives Positive CHMP Opinion

GSK's Shingrix Approved in China for Prevention of Shingles in Adults Aged 18 and over Who are at Increased Risk Due to Immunodeficiency or Immunosuppression

GSK plc to Report Q3, 2025 Results on Oct 29, 2025

GSK plc Announces Major Update to Vaccine Track

US Food and Drug Administration Accepts GSK plc's Gepotidacin as an Oral Option for the Treatment of Unplicated Urogenital Grogenital Grogenital Gonorrhoea

GSK plc Provides Update on US Settlement of CureVac/BioNTech mRNA Patent litigation

GSK plc Declares Second Interim Dividend for Second Quarter of 2025, Payable on 9 October 2025